Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population
Table 3
Association between therapeutic response and molecular biomarkers.
Total
Therapeutic response
value
Incomplete response, (%)
Complete response, (%)
Ki67
57
0.620
<50
16 (88.9)
2 (11.1)
≥50
34 (87.2)
5 (12.8)
MSI
57
0.220
Unstable
9 (81.8)
2 (18.2)
Stable
41 (89.1)
5 (10.9)
MSH6
Stable
57
47 (87)
7 (13)
0.100
Unstable
3 (100)
0 (0)
MSH2
57
Stable
48 (88.9)
6 (11.1)
0.330
Unstable
2 (66.7)
1 (33.3)
MLH1
57
Stable
48 (88.9)
6 (11.1)
0.330
Unstable
2 (66.7)
1 (33.3)
PMS2
57
Stable
47 (88.7)
6 (11.3)
0.417
Unstable
3 (75)
1 (25)
KRAS exon 2
57
Wild type
35 (85.4)
6 (14.6)
0.660
Mutated
15 (93.8)
1 (6.3)
KRAS exon 3
50
Wild type
44 (88)
6 (12)
Mutated
0 (0)
0 (0)
KRAS exon 4
51
Wild type
42 (89.4)
5 (10.6)
1.000
Mutated
4 (100)
0 (0)
NRAS exon 2
47
Wild type
41 (89.1)
5 (10.9)
1.000
Mutated
1 (100)
0 (0)
NRAS exon 3
57
Wild type
49 (87.5)
7 (12.5)
1.000
Mutated
1 (100)
0 (0)
NRAS exon 4
47
Wild type
40 (90.9)
4 (9.1)
Mutated
0 (0)
0 (0)
HER-2 scoring
57
0
37 (86)
6 (14)
0.810
1
7 (87.5)
1 (12.5)
2
3 (100)
3 (100)
3
3 (100)
0 (0)
p53
57
0.002
<20
6 (100)
0 (0.0)
20-50
4 (50)
4 (50)
≥50
40 (93)
3 (7)
value was not calculated because the variable is constant.
